Table 2.
Clinical characteristics of the nine clusters found in the focused handprint analysis
| Variables/clusters | C1 (n = 49) | C2 (n = 30) | C3 (n = 75) | C4 (n = 41) | C5 (n = 47) | C6 (n = 52) | C7 (n = 46) | C8 (n = 56) | C9 (n = 57) | P-value |
|---|---|---|---|---|---|---|---|---|---|---|
| Age at initial pathologic diagnosis (Yr) | 57.6 ± 13.2 | 53.5 ± 8.16 | 59.8 ± 10.7 | 61.1 ± 12 | 60.2 ± 9.67 | 63.4 ± 11.8 | 59.8 ± 12.5 | 59.4 ± 11.6 | 60 ± 11.4 | 3.40E-02 2 |
| Days from birth (Days) | −21,200 ± 4830 | −19,700 ± 3030 | −21,900 ± 3870 | −22,700 ± 4260 | −22,200 ± 2580 | − 23,300 ± 4290 | −22,000 ± 4560 | −21,900 ± 4240 | −22,200 ± 4140 | 3.15E-02 2 |
| Days to death (Days (IQR)) | 1220 (725–1490) | 1480 (1210–2360) | 997 (404–1230) | 949 (563–1360) | 787 (512–1340) | 1090 (680–1580) | 978 (536–1450) | 1070 (340–1440) | 1290 (731–1700) | 2.11E-02 1 |
| Days to last followup (Days (IQR)) | 1090 (689–1460) | 1200 (688–1550) | 664 (238–1120) | 763 (272–1820) | 676 (185–1560) | 804 (339–1560) | 651 (347–1370) | 816 (223–1370) | 1280 (605–1690) | 3.74E-02 1 |
| Initial pathologic diagnosis method | Cytology: 9; Excisional biopsy: 2; Fine needle aspiration biopsy: 2; Incisional biopsy: 4; Tumor resection: 32 | Cytology: 3; Excisional biopsy: 0; Fine needle aspiration biopsy: 0; Incisional biopsy: 0; Tumor resection: 27 | Cytology: 12; Excisional biopsy: 0; Fine needle aspiration biopsy: 3; Incisional biopsy: 0; Tumor resection: 59; NA: 1 | Cytology: 2; Excisional biopsy: 0; Fine needle aspiration biopsy: 2; Incisional biopsy: 1; Tumor resection: 36 | Cytology: 9; Excisional biopsy: 2; Fine needle aspiration biopsy: 0; Incisional biopsy: 2; Tumor resection: 33; NA: 1 | Cytology: 6; Excisional biopsy: 0; Fine needle aspiration biopsy: 1; Incisional biopsy: 0; Tumor resection: 44; NA: 1 | Cytology: 2; Excisional biopsy: 0; Fine needle aspiration biopsy: 0; Incisional biopsy: 0; Tumor resection: 44 | Cytology: 9; Excisional biopsy: 1; Fine needle aspiration biopsy: 0; Incisional biopsy: 3; Tumor resection: 43 | Cytology: 5; Excisional biopsy: 0; Fine needle aspiration biopsy: 1; Incisional biopsy: 0; Tumor resection: 51 | 3.28E-03 3 |
| Lymphatic invasion | No: 4; Yes: 9; NA: 36 | No: 6; Yes: 10; NA: 14 | No: 7; Yes: 19; NA: 49 | No: 13; Yes: 5; NA: 23 | No: 1; Yes: 17; NA: 29 | No: 13; Yes: 6; NA: 33 | No: 8; Yes: 21; NA: 17 | No: 4; Yes: 8; NA: 44 | No: 5; Yes: 14; NA: 38 | 2.43E-02 3 |
| Neoplasm histologic grade | G1: 1; G2: 13; G3: 33; G4: 0; Gb: 1; Gx: 1 | G1: 0; G2: 5; G3: 24; G4: 0; Gb: 0; Gx: 0; NA: 1 | G1: 0; G2: 5; G3: 70; G4: 0; Gb: 0; Gx: 0 | G1: 0; G2: 5; G3: 36; G4: 0; Gb: 0; Gx: 0 | G1: 0; G2: 6; G3: 39; G4: 0; Gb: 0; Gx: 2 | G1: 0; G2: 6; G3: 44; G4: 1; Gb: 0; Gx: 1 | G1: 0; G2: 8; G3: 38; G4: 0; Gb: 0; Gx: 0 | G1: 0; G2: 1; G3: 53; G4: 0; Gb: 0; Gx: 2 | G1: 0; G2: 6; G3: 49; G4: 0; Gb: 0; Gx: 1; NA: 1 | 1.89E-02 1 |
| Ethnicity | American Indian or Alaska native: 1; Asian: 1; Black or African American: 3; White: 43; NA: 1 | American Indian or Alaska native: 0; Asian: 1; Black or African American: 2; White: 27; NA: 0 | American Indian or Alaska native: 0; Asian: 3; Black or African American: 2; White: 68; NA: 2 | American Indian or Alaska native: 0; Asian: 1; Black or African American: 3; White: 37; NA: 0 | American Indian or Alaska native: 1; Asian: 1; Black or African American: 0; White: 41; NA: 4 | American Indian or Alaska native: 0; Asian: 2; Black or African American: 4; White: 44; NA: 2 | American Indian or Alaska native: 0; Asian: 3; Black or African American: 1; White: 41; NA: 1 | American Indian or Alaska native: 0; Asian: 3; Black or African American: 2; White: 49; NA: 2 | American Indian or Alaska native: 0; Asian: 0; Black or African American: 4; White: 51; NA: 2 | 6.72E-01 3 |
| Clinical stage | iia: 0; iib: 0; iic: 0; iiia: 1; iiib: 0; iiic: 38; iv: 10; NA: 0 | iia: 0; iib: 0; iic: 1; iiia: 0; iiib: 1; iiic: 24; iv: 3; NA: 1 | iia: 0; iib: 0; iic: 3; iiia: 1; iiib: 3; iiic: 51; iv: 16; NA: 1 | iia: 0; iib: 0; iic: 3; iiia: 4; iiib: 4; iiic: 22; iv: 7; NA: 1 | iia: 0; iib: 1; iic: 1; iiia: 0; iiib: 2; iiic: 33; iv: 9; NA: 1 | iia: 0; iib: 0; iic: 2; iiia: 1; iiib: 5; iiic: 38; iv: 6; NA: 0 | iia: 1; iib: 1; iic: 2; iiia: 0; iiib: 4; iiic: 34; iv: 4; NA: 0 | iia: 0; iib: 0; iic: 1; iiia: 0; iiib: 1; iiic: 42; iv: 12; NA: 0 | iia: 2; iib: 2; iic: 4; iiia: 0; iiib: 1; iiic: 41; iv: 7; NA: 0 | 2.65E-02 1 |
| Tumor residual disease | > 20 mm: 10; 1–10 mm: 26; 11–20 mm: 6; no macroscopic disease: 4; NA: 3 | > 20 mm: 5; 1–10 mm: 17; 11–20 mm: 5; no macroscopic disease: 12; NA: 4 | > 20 mm: 17; 1–10 mm: 29; 11–20 mm: 5; no macroscopic disease: 12; NA: 12 | > 20 mm: 6; 1–10 mm: 18; 11–20 mm: 1; no macroscopic disease: 12; NA: 4 | > 20 mm: 11; 1–10 mm: 21; 11–20 mm: 4; no macroscopic disease: 3; NA: 8 | > 20 mm: 4; 1–10 mm: 24; 11–20 mm: 5; no macroscopic disease: 12; NA: 7 | > 20 mm: 8; 1–10 mm: 15; 11–20 mm: 5; no macroscopic disease: 13; NA: 5 | > 20 mm: 6; 1–10 mm: 29; 11–20 mm: 2; no macroscopic disease: 14; NA: 5 | > 20 mm: 11; 1–10 mm: 25; 11–20 mm: 2; no macroscopic disease: 14; NA: 5 | 6.13E-02 1 |
| Tumor tissue site | Omentum: 0; Ovary: 48; Peritoneum ovary: 1 | Omentum: 0; Ovary: 30; Peritoneum ovary: 0 | Omentum: 1; Ovary: 74; Peritoneum ovary: 0 | Omentum: 0; Ovary: 41; Peritoneum ovary: 0 | Omentum: 1; Ovary: 46; Peritoneum ovary: 0 | Omentum: 0; Ovary: 52; Peritoneum ovary: 0 | Omentum: 0; Ovary: 46; Peritoneum ovary: 0 | Omentum: 0; Ovary: 56; Peritoneum ovary: 0 | Omentum: 0; Ovary: 57; Peritoneum ovary: 0 | 5.01E-01 3 |
| Venous invasion | No: 3; Yes: 3; NA: 43 | No: 3; Yes: 10; NA: 17 | No: 8; Yes: 7; NA: 60 | No: 12; Yes: 3; NA: 26 | No: 1; Yes: 10; NA: 36 | No: 10; Yes: 5; NA: 37 | No: 7; Yes: 20; NA: 19 | No: 3; Yes: 1; NA: 52 | No: 3; Yes: 10; NA: 44 | 7.24E-02 3 |
| Vital status | Alive: 9; Dead: 40, NA: 0 | Alive: 14; Dead: 16; NA: 0 | Alive: 33; Dead: 42; NA:0 | Alive: 18; Dead: 23; NA: 0 | Alive: 20; Dead: 27; NA: | Alive: 20; Dead: 31; NA: 1 | Alive: 28; Dead: 18; NA: 0 | Alive: 31; Dead: 25; NA: 0 | Alive: 27; Dead: 30; NA: 0 | 1.90E-03 3 |
| Primary therapy outcome success | Complete remission/response: 24; Partial remission/response: 12; Progressive disease: 3; Stable disease: 1; NA: 9 | Complete remission/response: 17; Partial remission/response: 3; Progressive disease: 4; Stable disease: 2; NA: 4 | Complete remission/response: 41; Partial remission/response: 7; Progressive disease: 2; Stable disease: 4; NA: 21 | Complete remission/response: 24; Partial remission/response: 4; Progressive disease: 2; Stable disease: 0; NA: 11 | Complete remission/response: 24; Partial remission/response: 8; Progressive disease: 4; Stable disease: 3; NA: 8 | Complete remission/response: 29; Partial remission/response: 6; Progressive disease: 1; Stable disease: 5; NA: 11 | Complete remission/response: 27; Partial remission/response: 5; Progressive disease: 4; Stable disease: 6; NA: 4 | Complete remission/response: 36; Partial remission/response: 4; Progressive disease: 7; Stable disease: 2; NA: 7 | Complete remission/response: 35; Partial remission/response: 5; Progressive disease: 5; Stable disease: 1; NA: 11 | 5.08E-01 1 |
| Days lived known | 22,300 ± 4750 | 21,100 ± 3150 | 22,800 ± 3930 | 23,800 ± 4050 | 23,300 ± 3840 | 24,500 ± 4140 | 23,000 ± 4490 | 22,800 ± 4430 | 23,400 ± 4240 | 3.85E-02 2 |
Nominally statistically significant differences (p < 0.05) are shown in italic. Interestingly, significant differences are detected in lymphatic invasion, clinical stage at diagnosis, vital status and the overall number of days alive